Ocular Therapeutix (OCUL) Reports In-Line Q4 EPS

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.44 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• BTIG Assumes Essent Group (ESNT) at Neutral
• Raymond James Starts Western Alliance Bancorporation (WAL) at Outperform